Markets
BIO34812 (BIO34812)
BIO34812Stock
–
– (–) today
Last price
– 1D
- Market cap
- –
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- –
- Average volume
- –
- Previous close
- –
Analysts
2 coveringHold1 buy, 1 hold, 0 sell
Targets a year out average $440.00
$440.00now –$440.00
Earnings
next estimate $2.59Next report
Dec 2025
-2.3%
Mar 2026
-31.8%
Jun 2026
+12.0%
Sep 2026
+1.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $693.20m | $592.10m | $651.00m | $656.40m |
| Gross profit | $345.20m | $309.40m | $345.80m | $328.60m |
| Operating income | -$118.90m | $34.10m | $72.60m | -$49.70m |
| Net income | $720.00m | -$527.10m | $371.40m | $458.60m |
Last four quarters: revenue $2.59bn, margin 39.5%, free cash flow $329.10m
News
8 latest- Why Bio-Rad (BIO) International Revenue Trends Deserve Your AttentionZacks · 6 days ago
- Bio-Rad (BIO) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 5, 2026
- What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings CallMarketBeat · Nov 5, 2026
- Bio-Rad Laboratories (BIO) Q3 Earnings Top EstimatesZacks · Nov 4, 2026
- Neogen (NEOG) Q1 Earnings and Revenues Beat EstimatesZacks · Oct 6, 2026
- Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsZacks · Sep 28, 2026
- Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher RTTNews · Sep 27, 2026
- Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A GrowthMarketBeat · Sep 25, 2026
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.